BioSpace News Archive

Tissue from presymptomatic patient in Italy was found to contain SARS-CoV-2 using Company’s Logix Smart™ COVID-19 test kit

Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, announced that management will participate in the Jefferies 2020 Virtual Healthcare Conference being held from June 2-4, 2020.

Merck to Apply its Industry-Leading Vaccine Development Capabilities to SARS-CoV-2 Vaccine Program Originated by Themis and Institut Pasteur

Decreasing LIGHT levels using CERC-002 (anti-LIGHT mAb) may prevent cytokine storm induced severe ARDS and thereby reduce mortality and the need for ventilation

Rockwell Medical, Inc., a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, announced the filing of a New Drug Submission with Health Canada for Triferic AVNU.

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced that management will host investor conference calls through June

BioCryst Pharmaceuticals, Inc. announced that the company will present new data on berotralstat, an oral, once-daily therapy under regulatory review in the United States, Japan and the European Union for the prevention of hereditary angioedema attacks, at the upcoming digital congress of the European Academy of Allergy and Clinical Immunology June 6-8.

Sierra Oncology, Inc., a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, announced the appointment of Dr. Stephen Dilly as President and Chief Executive Officer, effective June 1, 2020.

Hutchison China MediTech Limited and BeiGene, Ltd. announced that they have entered into a clinical collaboration agreement to evaluate the safety, tolerability and efficacy of combining two of Chi-Med’s drug candidates, surufatinib and fruquintinib, with BeiGene’s anti-PD-1 antibody tislelizumab, for the treatment of various solid tumor cancers, in the U.S., Europe, China and Australia.

Novasep announced the signature of an agreement for the development and manufacturing of LYS-GM101, an AAVrh10-based gene therapy drug candidate for the treatment of GM1 Gangliosidosis, a rare neuronopathic lysosomal storage disorder.